GENMAB A/S
GENMAB A/S is a Healthcare company operating in Biotechnology with a $15.72B market cap.
Most recent earnings call: Q1 FY26 on May 14, 2026.
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks GMAB's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GMAB.
$ curl https://api.spokenalpha.com/v1/companies/GMABFAQ
Spoken Alpha indexes GMAB's earnings call transcripts at https://spokenalpha.com/companies/GMAB. Each call links to attributed speakers and parsed analyst Q&A. GENMAB A/S's own investor relations page is at https://www.genmab.com/investor-relations.
GENMAB A/S (GMAB) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
GENMAB A/S (GMAB) operates in the Healthcare sector (Biotechnology industry).
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $5.01 | $4.15 | +20.7% | +2.5% | +4.2% |
| Q4 FY2026 | $4.78 | $4.25 | +12.4% | +0.3% | -1.9% |
| Q3 FY2026 | $5.02 | $4.28 | +17.4% | -3.5% | -4.5% |
| Q2 FY2026 | $4.81 | $4.25 | +13.1% | +5.0% | +3.2% |
| Q1 FY2025 | $5.04 | $4.25 | +18.7% | -0.6% | +0.2% |
| Q4 FY2025 |
| $5.07 |
| $4.43 |
| +14.5% |
| -0.5% |
| +1.3% |
| Q3 FY2025 | $4.90 | $4.43 | +10.7% | -5.2% | -7.7% |
| Q2 FY2025 | $5.09 | $4.43 | +15.0% | -2.3% | -0.7% |
| Q1 FY2024 | $5.19 | $4.27 | +21.5% | +1.2% | +3.3% |
| Q4 FY2024 | $4.97 | $4.36 | +14.0% | +3.9% | +5.4% |